- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
NPPA fixes retail prices of 15 formulations, ceiling price of Framycetin
New Delhi: National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India has fixed retail prices of 15 formulations and a ceiling price of 1 scheduled formulation under Drugs (Prices Control) Order, 2013.
The authority has fixed the prices based on the decision of the 96th Authority meeting dated 24.03.2022.
Retail prices of 15 formulations
The formulations include Exemed Pharma and Emcure Pharma's Dapagliflozin plus Metformin Hydrochloride Extended release Tablet, Synokem Pharma and Natco Pharma's Dapagliflozin plus Metformin Hydrochloride (As Extended release form) Tablet, MSN Labs and USV Limited's Dapagliflozin plus Metformin Hydrochloride Extended release Tablet, Intas Pharma's Human Normal Immunoglobulin for Intravenous use IP 5% (Ig M Enriched), Synokem Pharma and Serum Institute of India's Medroxyprogestero ne Acetate sustained release Tablet.
This comes after in exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1. | Metformin (extended-release) + Teneligliptin Tablet | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 500mg (as Extended- Release) Teneligliptin Hydrobromide hydrate eq. to Teneligliptin 20mg | 1 Tablet | M/s Associated Biotech / M/s Dales Laboratories | 7.14 |
2. | Dapagliflozin + Metformin Hydrochloride Extended release Tablet | Each film-coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg, Metformin Hydrochloride IP 1000mg (As Extended release form) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited | 10.70 |
3. | Dapagliflozin + Metformin Hydrochloride (As Extended release form) Tablet | Each film-coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg, Metformin Hydrochloride IP 1000mg (As Extended release form) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Natco Pharma Ltd. | 7.97 |
4. | Dapagliflozin + Metformin Hydrochloride (As Extended release form) Tablet | Each film-coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg, Metformin Hydrochloride IP 1000mg (As Extended release form) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Apex Laboratories Private Limited | 10.70 |
5. | Dapagliflozin + Metformin Hydrochloride Extended release Tablet | Each film-coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg, Metformin Hydrochloride IP 500mg (As Extended release form) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited | 9.18 |
6. | Dapagliflozin + Metformin Hydrochloride (As Extended release form) Tablet | Each film-coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg, Metformin Hydrochloride IP 500mg (As Extended release form) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Natco Pharma Ltd. | 7.30 |
7. | Dapagliflozin + Metformin Hydrochloride (As Extended release form) Tablet | Each film-coated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg, Metformin Hydrochloride IP 500mg (As extended release form) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Apex Laboratories Private Limited | 9.18 |
8. | Dapagliflozin + Metformin Hydrochloride Extended release Tablet | Each film-coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg, Metformin Hydrochloride IP 1000mg (As extended release form) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited | 7.29 |
9. | Dapagliflozin + Metformin Hydrochloride Extended release Tablet | Each film-coated tablet contains: Dapagliflozin 5mg, Metformin Hydrochloride IP/USP 1000mg (As extended release form) | 1 Tablet | M/s MSN Laboratories Pvt. Ltd. / M/s USV Limited | 7.29 |
10. | Dapagliflozin + Metformin Hydrochloride Extended release Tablet | Each film-coated tablet contains: Dapagliflozin 5mg, Metformin Hydrochloride IP/USP 500mg (As extended release form) | 1 Tablet | M/s MSN Laboratories Pvt. Ltd. / M/s USV Limited | 6.16 |
11. | Human Normal Immunoglobulin for Intravenous use IP 5% (Ig M Enriched) | Each vial contains: Total Protein 50 g/L, Immunoglobulin M 6g/L, Immunoglobulin A 6g/L, Immunoglobulin G 38g/L, Glucose Monohydrate (as stabilizer) 27.5g/L, Sodium Chloride 4.56g/L, Water for injection q. s. Distribution of Ig G subclass is approx. 62%IgG1,27%IgG2,1%IgG3, 10%IgG4 | Per 1 ml (for 10 ml vial) | M/s Intas Pharmaceuticals Ltd | 177.85 |
12. | Medroxyprogestero ne Acetate sustained release Tablet | Each uncoated sustained release tablet contains: Medroxyprogesterone Acetate IP 30mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Serum Institute of India Pvt. Ltd. | 14.04 |
13. | Medroxyprogestero ne Acetate SR Tablet | Each uncoated sustained release tablet contains: Medroxyprogesterone Acetate IP 30mg | 1 Tablet | M/s Synokem Pharmaceuticals Limited / M/s Torrent Pharmaceuticals Ltd. | 14.04 |
14. | Glycopyrrolate + Formoterol Fumarate + Budesonide Inhalation | Each actuation delivers: Glycopyrrolate IP 9mcg Formoterol Fumarate Dihydrate IP eq. to Formoterol Fumarate 4.8mcg Budesonide IP 160mcg | 1 MDI | M/s Zydus Healthcare Ltd. | 8.63 |
15. | Folic Acid, Pyridoxine Hydrochloride, Methylcobalamin & Vitamin D3 Tablet | Each uncoated mouth dissolving tablet contains: Folic Acid IP 5mg Pyridoxine Hydrochloride IP 3mg Methylcobalamin IP 1500mcg Vitamin D3 IP 1000 IU | 1 tablet | M/s Unison Pharmaceuticals Pvt. Ltd. | 6.70 |
Sl. No. | Name of the Scheduled Formulation | Dosage form & Strength | Unit | Ceiling Price (Rs. |
(1) | (2) | (3) | (4) | (5) |
1. | Framycetin | Cream 0.5% | 1 GM | 1.19 |
For more details, check out the full notice on the link below:
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751